title: [A postoperative infectious complication in a patient with rheumatoid arthritis treated with adalimumab].
abstract: Tumor necrosis factor (TNF) blocking agents, such as adalimumab, are well tolerated and provide improvement in the symptoms and signs of rheumatoid arthritis (RA). Due to its immunosuppressive effect, an increased risk of infection has been suggested, but so far no differences between adalimumab and placebo groups have been found in pivotal trials. Patients with RA succumb to postoperative complications because they have a systemic disease and use medication with immunosuppressive effects. We report on a patient with longstanding, active RA who had received adalimumab 40 mg every other week with prolonged infection, wound dehiscence and pseudoarthrosis following reconstructive forefoot surgery due to deformities secondary to RA. The postoperative infection occurred although adalimumab therapy had been stopped 8 days before surgery. The half-life of adalimumab is 10.0-13.6 days following a single intravenous dose. Whether patients under therapy with adalimumab are at an increased risk of developing postoperative complications is unclear, a retrospective analysis of the pivotal studies would be helpful in estimating the risk of perioperative (wound) infections in patients receiving anti-TNF. Moreover, it is not clear when therapy should be stopped prior to surgical intervention. Obviously prospective clinical trials would be more convincing.
authors.affiliation: Universitätsklinik für Orthopädie, Medizinische Universität, Währinger Gürtel 18-20, 1090, Wien, Osterreich. martin.pfeiffer@gmx.at
authors.forename: M
authors.initials: M
authors.lastname: Pfeiffer
authors.forename: M
authors.initials: M
authors.lastname: Köller
authors.forename: A
authors.initials: A
authors.lastname: Wanivenhaus
authors.forename: K
authors.initials: K
authors.lastname: Trieb
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005531:Foot Deformities, Acquired / Q000601:surgery*; D005545:Forefoot, Human / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011542:Pseudarthrosis / Q000139:chemically induced / Q000175:diagnosis / Q000601:surgery; D012086:Reoperation; D013529:Surgical Wound Dehiscence / Q000139:chemically induced / Q000175:diagnosis / Q000601:surgery; D013530:Surgical Wound Infection / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000068879:Adalimumab